Device Trial Radar · NCT04113811
Microwave Needle Thermoablation for Treatment of Localized Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Oct 8, 2019
Primary completion
Feb 16, 2023
Study completion Apr 11, 2023
Sponsor
- Lead sponsor
- Chinese University of Hong KongAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 3, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- Male only, from 45 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Conventional treatment options for localized prostate cancer include prostatectomy, radiotherapy and active surveillance. However, prostatectomy and radiotherapy carry certain degree of morbidity, including the risks of urinary incontinence, erectile dysfunction and injury to the surrounding organs like rectum and bladder. Active surveillance carries the risk of disease progression and psychological distress to the patients. Focal therapy employs the concept of only destroying the target lesion without treating other benign areas, resulting in disease cure in majority of cases with less treatment morbidity. Microwave treatment to the prostate has been performed since more than 20 years ago for benign prostatic hyperplasia and is approved by FDA in United States. It exerts its effect through thermal destruction of prostate tissue. Targeted treatment of localized prostate cancer using microwave needle ablation guided by MRI and Ultrasound imaging has been performed recently and was shown to be safe and effective. Our study aims to assess the effectiveness of this focal therapy in treating localized prostate cancer.
Conditions
- Prostate Cancer
Interventions
Biomedical TATO3® Microwave needle thermoablation device (Koelis, Grenoble, France)Device
In this study, we plan to investigate oncological outcome of fusion-guided microwave needle therapy using transperineal (TP) approach
Primary outcomes
What the sponsor says the trial is designed to measure.
- The oncological control of prostate cancerTime frame: At 6 months after treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Prince of Wales Hospital, Chinese University of Hong Kong
Hong Kong, Hong Kong
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.